Sagimet Biosciences Inc. operates primarily in the United States and focuses on the discovery and development of selective FASN inhibitors. The company's lead clinical program, denifanstat, is designed to reduce excess liver fat, decrease inflammation, and blunt fibrosis in patients with MASH, and has received Breakthrough Therapy designation from the FDA. In addition to liver diseases, Sagimet is exploring the use of denifanstat and its pipeline candidate, TVB-3567, for the treatment of moderate to severe acne and select forms of cancer, such as recurrent glioblastoma. The company partners with Ascletis BioScience to test and develop its candidates in China. Originally incorporated in 2006 and formerly known as 3-V Biosciences, the company rebranded to Sagimet Biosciences in 2019.
